BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
0.1860
-0.0115 (-5.82%)
At close: May 13, 2026, 4:00 PM EDT
0.1860
0.00 (0.00%)
Pre-market: May 14, 2026, 5:57 AM EDT
BioRestorative Therapies Employees
As of December 31, 2025, BioRestorative Therapies had 14 total employees, including 13 full-time and 1 part-time employees. The number of employees increased by 3 or 27.27% compared to the previous year.
Employees
14
Change (1Y)
3
Growth (1Y)
27.27%
Revenue / Employee
$25,693
Profits / Employee
-$1,017,284
Market Cap
4.74M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 3 | 27.27% | 13 | 1 |
| Dec 31, 2024 | 11 | 0 | - | 11 | 0 |
| Dec 31, 2023 | 11 | 1 | 10.00% | 11 | 0 |
| Dec 31, 2022 | 10 | 3 | 42.86% | 10 | 0 |
| Dec 31, 2021 | 7 | 2 | 40.00% | 7 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BiomX | 20 |
| GeoVax Labs | 19 |
| Cardio Diagnostics Holdings | 17 |
| FibroBiologics | 15 |
| Dermata Therapeutics | 9 |
| MetaVia | 8 |
| CNS Pharmaceuticals | 5 |
| Mustang Bio | 4 |
BRTX News
- 15 hours ago - BioRestorative Therapies presents preclinical data on MSC exosome proteomics - TheFly
- 19 hours ago - BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals - GlobeNewsWire
- 6 days ago - BioRestorative Therapies reports expanded Phase 2 blinded dataset for BRTX-100 - TheFly
- 6 days ago - BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease - GlobeNewsWire
- 13 days ago - BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform - GlobeNewsWire
- 22 days ago - BioRestorative Therapies announces partnership with David Goldberg, M.D. - TheFly
- 22 days ago - BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical Platform - GlobeNewsWire
- 5 weeks ago - BioRestorative Therapies announces strategic collaboration with 203 Creates - TheFly